

ANIMAL HEALTH INNOVATION USA INNOVATION SHOWCASE FINALISTS 2021

15-16 June • Virtual Event • @AHInnovation #AHInnovationUSA

Animal Health Innovation USA is the premier investment forum showcasing the most exciting investment opportunities in animal health and nutrition. It connects those businesses with financial investors and strategic corporate partners.



We are proud to announce the 20 finalist companies selected to present at the 2021 Animal Health Innovation USA Showcase.

Associate Partners



A SPECIAL THANK YOU TO THE SELECTION COMMITTEE

The Selection Committee members were responsible for selecting the showcase companies at Animal Health Innovation USA 2021. Each of our committee members has an extensive breadth of experience and knowledge across animal health and nutrition industries and will be available for meetings at the conference.



Randolph Seidler
Venture Partner
Anterra Capital



Tony Simpson
President
AgTech Advisors, LLC



Rob Readnour
Mountain Group Capital



Amanda Burkhardt
Founder & CEO
Nutripeutics



Sebastien Lafon
Independent Animal Health
Expert



Lauren Carde
VP Operations and
Regulatory Affairs
Paul Dick & Associates Ltd



Brian Axe
Principal
**Nova Quest Capital
Management**



Dino Dedić, CFA
Managing Director,
Healthcare Investment
Banking
Barclays



Lydia Kinkade
Managing Director at **iiM**;
Director at **Cohen-Esrey
Capital Partners**



Kevin Lockett
Partner
Fulcrum Global Capital





VIRTUAL. NETWORKING. REIMAGINED.

Animal Health Innovation USA is committed to bringing innovative and inspiring emerging companies together with partners looking to acquire and invest.

We have advanced our networking capabilities to help you recreate the unexpected business interactions that are so valuable at our face-to-face events.

This includes:

Virtual roundtable discussions of 8 people
Workshop groups of 20+ people
Interactive content delivery

Virtual Networking Roulette- Engage in unexpected interactions and perhaps uncover a new opportunity

You will still have access to our **MEETING MOJO** platform, which allows you to create a bespoke meeting schedule, ensuring you connect with the industry stakeholders that are most important in building your business.

MEETING MOJO gives you access to the entire attendee list and allows you to message AND invite people to connect during the formal meeting sessions run throughout the day.



SCHEDULED MEETINGS

Who You Will Meet

- + Start-Ups & Early Stage Biotech Companies
- + Business Development Teams from International Pharmaceutical Companies
- + Leadership from Multinational Corporations
- + Mid to late-stage Health and Nutrition Companies
- + Global Distribution Leaders
- + Venture Capital and Private Equity Investors
- + Market Intelligence and Consultancy Providers
- + Universities and National Regulatory Bodies
- + Contract Research & Contract Manufacturing

Join the Finalists:
REGISTER TODAY



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Jeff Barnes

President
Aimalojic



Late-Stage company seeking \$10 million+

Company Value Proposition

AimaLojic, Inc. has developed and manufactures a life-saving device for pets poisoned with drugs, chemicals, toxic plants or envenomation. Current therapies often require multiple days in the ICU and even with best efforts can result in mortality or long term organ damage. AimaLojic's blood filtering technology can completely purify blood of a wide range of toxins in as little as one hour.

AimaLojic, Inc. (Aima is Greek for "blood"), is a wholly-owned subsidiary of ImmutriX Therapeutics, Inc., which had developed a blood purification technology capable of removing toxins and other molecules from whole blood. The therapy, called hemoperfusion or hemoadsorption, can selectively filter unwanted molecules from the body in a process similar to hemodialysis. The first products being sold are for companion animals involved in an overdose or toxicosis as a result of poison or drug ingestion or envenomation, with a pipeline of products to be used in other disease conditions.

About the Speaker

Jeff Barnes has been in the medical device industry for about 30 years, involved in many aspects of product development, clinical applications, sales and management. He began his career as a technical specialist for products that were commercialized and revolutionized radial keratotomy vision correction surgery in the early 1990s. He was subsequently a subject matter expert in automated lamellar keratoplasty that became the first and dominant surgical and diagnostic devices for LASIK eye surgery. Bausch & Lomb and Abbott acquired four of the startups that Barnes was involved with. In 2012 Barnes cofounded ImmutriX Therapeutics Inc., and subsidiary AimaLojic Animal Health, working on a novel technology for blood purification. He and his team have taken the concept from inception to clinical use and are preparing to launch a blood purification system in veterinary and human medicine for drug overdose and other disease conditions.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



hilltop bio

Amanda Drobnis

Co-Founder & CEO
Hilltop BioSciences



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Hilltop Bio's revolutionary treatment allows our vets to have an off-the-shelf, effective product, that does not require large capital investment or training. Our products easily treat soft tissue injuries or inflammatory diseases that likely would have required lifetime medication. This helps our pets have a higher quality of life while saving money for our pet parents.

Our products are based on years of research in human and veterinary medicine in birth tissues, exosomes, and other components that allow the body to heal itself with some support from an off-the-shelf product. We have developed ways to up-regulate and down-regulate certain components within the tissue to treat a wide array of indications within veterinary medicine.

About the Speaker

Amanda Drobnis is the Co-Founder and CEO of Hilltop BioSciences. She has spent many years looking for ways to combine her passion for animals (especially horses) with business. First working for a non-profit planning large conferences and events and then in marketing for a large pet retail company. She then moved on to sales and marketing for several medical and veterinary companies. Before founding Hilltop Bio, Amanda co-founded and managed a New England based medical regenerative therapy distribution company that continues to thrive and grow today. When not at Hilltop Bio's lab Amanda can be found riding her favorite horse, Addie, or lost in a great book!



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Kubanda
CRYOTHERAPY

Bailey Surtees

CEO

Kubanda Cryotherapy



Pre-Series B company seeking up to \$2 million

Company Value Proposition

More than 25% of pets are expected to develop a tumor in their lifetime. However, the standard of care hasn't progressed past invasive surgical mass removal, which can be risky and expensive - particularly for benign masses. More than 15M owners each year are left searching for better answers.

Our system enables vets to treat lumps, bumps, and cancers with a safe and minimally invasive solution. With a needle poke instead of an incision, cryotherapy is a care decision that's easier on everyone.

We've validated our system through rigorous clinical trials and are currently rolling out an early-adopter program. Working with select clinics representative of key market segments, we can gain critical insights before broader market entry.

About the Speaker

Having expanded Kubanda from idea to commercial enterprise, Bailey now serves as company CEO. She develops the company's strategic focus and vision, oversees all operations, and engages and expands Kubanda's network with business and technical professionals.




INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Wesley Wierson

Founder & CEO

LEAH Laboratories



Pre-Series B company seeking up to \$2 million

Company Value Proposition

LEAH Labs was founded in late 2018 to be “the gene editing companion animal health company.” We are built of gene editors, cell biologists, veterinary oncologists and pharmacologists, and human cell therapy physicians with deep expertise in our scientific platform.

We’re primarily focused on the canine oncology market, where 6,000,000 dogs die every year. As a first indication, we’re targeting B cell lymphoma, a cancer that kills >250,000 dogs every for which the standard of care is a \$10,000 chemotherapy regimen that only buys 10 months of life.

Our platform technology and unique regulatory pathway will permit us to bring living therapies to companion animal health that have never before been possible without gene editing. In the future, we aim to partner with human pharma companies to trial early-stage, novel cell therapy strategies in natural, spontaneous disease in dogs through “compassionate use.” This will give dogs a chance at a healthy life, while allowing us to glean valuable clinical insight as pre-IND and/or IND-enabling studies.

About the Speaker

Wesley A. Wierson PhD, founder and CEO of LEAH Labs, is a passionate scientist and entrepreneur applying his expertise in gene editing technology to solve consumer level problems. He studied microbiology as an undergraduate, where he was first exposed to gene editing technology. As a PhD student, he developed gene editing technology that permits the integration of exogenous genes into the genome with precision, thus giving cells new functions, allowing scientists to study biology and genetics and to engineer living therapies.

Wes founded LEAH Labs in late 2018 to bring living cell therapies to dogs. LEAH Labs is first focused on translating a breakthrough, FDA approved cell therapy called CAR-T cell therapy to dogs with B cell lymphoma. Not only does this approach bring the potential to disrupt a decades old standard of care for our pets, LEAH Labs also aims to trial novel cell therapies in canine models of spontaneous disease to give dogs a chance at life and to accelerate human drug development timelines.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Alon Landa

CEO
MedcoVet



Pre-Series B company seeking up to \$2 million

Company Value Proposition

The use of laser therapy on pets has been widely proven to relieve pain and expedite healing. While laser therapy works, treatment in the clinic is expensive and inconvenient.

MedcoVet has created an innovative photobiomodulation (aka Laser Therapy) solution that's helping veterinarians move treatment from the clinic into the home while still compensating veterinarians for monitoring treatment. MedcoVet frees up the veterinarian, saves time and cost for the pet owner and reduces the strain on the pet in pain.

The company has had continual month-over-month growth, even throughout the Covid-19 pandemic.

About the Speaker

Alon Landa, MedcoVet CEO has 20+ years of experience leading technology startups across many fields including satellites, medical devices, Internet media, and has even written an app to help people prepare for a new furry friend (called PupReady). Over the last 15 years, Alon has started companies that leverage the Web to bring existing products to more customers. His latest company, MedcoVet, uses the Web to change the economics of laser therapy while increasing the connection between veterinarian and pet owner.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Albert J. Di Rienzo

Co-Founder, President & Chief Innovation Officer
One Health Group



Series B+ company seeking \$2-10 million

Company Value Proposition

Animal health practitioners cannot easily, accurately, inexpensively, and noninvasively (i.e., noncontact) collect actionable, context-based diagnostics, monitor patient health, predict adverse health events, and ensure compliance for a wide variety of health states anywhere, at anytime via a self-calibrating solution that's user-friendly, safe, unobtrusive and ergonomic, and which doesn't require any special training for them or their staff.

About the Speaker

In a span of nearly 30 years, Albert's career has focused on innovation in academia, government and industry, where he has been intimately involved with bringing over one hundred animal and human health solutions to market. In 2017, Albert Cofounded One Health Group, which is a for-profit company that's focused on the intersection of animal and human health; the Company is initially entering the animal health diagnostic and monitoring market via its noncontact, clinical-grade solution called Voyce.

OHG is a health technology innovator that's initially focused on animal health by leveraging its proven, patented Ultra-WideBand radar technology to translate digital biomarkers into actionable, clinical-grade information. Our solution (Voyce) consists of a noncontact intelligent sensor, which wirelessly communicates actionable health data anywhere, at any time via a mobile app and cloud-based dashboard. Our solution works for companion and production animals.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Daniel Grosu
CEO & President
PetDx



Series B+ company seeking \$2-10 million

Company Value Proposition

PetDx is a molecular diagnostics startup focused on the development of non-invasive tests for the detection, characterization, and management of cancer in pets, starting with dogs. We are building a portfolio of diagnostic solutions for multiple use cases across the continuum of cancer care, enabled by advances in cancer genomics and next-generation sequencing (NGS) technology, that offer high clinical utility and address a massive unmet need in veterinary medicine. Over 6M canine cancer cases are diagnosed each year in the US in a population of approximately 90M dogs. Noninvasive detection of cancer can save millions of lives each year. The TAM is over \$30B in the US alone, with a serviceable addressable market (SAM) in excess of \$10B.

About the Speaker

Daniel Grosu, MD, MBA, serves as the Chief Executive Officer and President for PetDx, and acts as the Chairman of its Board of Directors.

Daniel founded PetDx in early 2019 as a result of witnessing his beloved dog Poppy fight a losing battle with pancreatic cancer. She passed away at the age of four, less than two months after diagnosis. The experience motivated him to bring together a team of experts in genomics and veterinary medicine around a simple goal – the early detection of cancer in pets, using the most advanced molecular diagnostic methods available today.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS

Telenostic
for targeted treatment

Craig Mincher

Veterinary & Clinical Director
Telenostic



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Telenostic is an Irish technology/diagnostic company using data and AI image recognition technology to identify and quantify parasites in faecal samples. The technology, which primarily consists of an electronic sample reader and in-built software, has been developed in response to growing parasitic resistance in animals worldwide. The global IP for the technology has been developed and secured in partnership with University College Dublin (UCD) & Telenostic Limited.

About the Speaker

Craig is an experienced innovator and entrepreneur with a veterinary degree and MBA. 25 years experience in Animal Health including 16 years in business leadership. Has successfully built a leading veterinary pharmaceutical company in the Animal Health space. A visionary with deep insights into the South African Animal Health market and experience in new product development, regulatory environment, sales, marketing, strategy, supply chain and financial management.

While companion animals represent the initial target market, this is a global platform technology with applications across a number of verticals, including (i) companion animals, (ii) production animals, (iii) human faecal testing (particularly in developing nations) and (iv) environmental testing.

Early adoption of the technology is heavily underpinned by new EU regulations, which will be implemented in 2022. These new regulations will place a regulatory requirement for evidence-based testing (such as Telenostic's technology) for the prescription of medicines to animals in Europe.

Testing for parasitic infection is one of the most commonly undertaken veterinarian tests across the globe.

The Telenostic technology is fully automated and patent protected and uses digital imaging analysis and artificial intelligence to analyse samples across a wide range of species. Telenostic is unique and disruptive as it can be deployed for a fraction of the cost relative to existing testing methods, which are typically slow, inconsistent and require a trained technician or veterinarian to manually read samples under a microscope.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Ashley Kalinauskas
Founder & CEO
Torigen Pharmaceuticals



Series B+ company seeking \$2-10 million

Company Value Proposition

Torigen Pharmaceuticals, Inc. is a development stage biopharmaceutical company focused on providing cutting-edge therapeutics to the veterinary market. The companion animal health market is rapidly expanding, forecasted to reach \$20 billion in pet owner spend by 2023. Additionally, cancer is a big problem facing companion animals, with 4-6 million dogs and 4-6 million cats being diagnosed with cancer each year. We fill an innovation gap that exists in this market with our personalized cancer immunotherapy, Vetivax™, a technology created at the University of Notre Dame which utilizes a surgically resected portion of tumor to create a series of personalized cancer vaccines that are administered back to that patient to help prevent the cancer from progressing and metastasizing.

Torigen offers the only safe, effective and affordable cancer treatment option available to general practice veterinarians, and has been used to treat over 1,000 patients to date. Torigen Pharmaceuticals has developed a breakthrough product with Vetivax, and has made significant progress with the development of this technology.

Torigen has brought together one of the top teams in the animal health industry. We combine our expertise in research, veterinary medicine and commercial development to continue to commercialize not only our current product, but additional products are being evaluated for in-licensure. It is our goal to have 3 products on the market within the next 3 years allowing Torigen to be the leader in veterinary oncology.

About the Speaker

Ashley is the Founder and CEO of Torigen Pharmaceuticals—a startup that resulted from her graduate thesis project at the University of Notre Dame. Ashley graduated from the University of Connecticut in 2012 with an undergraduate degree in Pathobiology and then chose to continue her education. Torigen and its first product, Vetivax, are based upon the research of former University of Notre Dame professor Dr. Mark Suckow.

Torigen focuses on providing veterinary cancer care solutions for companion animals. Torigen's first product, Vetivax, is an autologous cancer immunotherapy that uses the patient's own tumor cells to create a personalized treatment to fight the cancer. With over 50% of companion animals over the age of 10 dying from cancer and with other treatment modalities being both expensive and having negative side effects, Vetivax is an innovative new treatment that is quickly gaining traction with veterinarians across the country.



INNOVATION SHOWCASE FINALISTS COMPANION ANIMALS



Adriann Sax

Co-Founder & CEO
Vetigenics



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Vetigenics is an early stage, animal health biotechnology company devoted to improving the health and well-being of companion animals by making the life-saving benefits of immunotherapy available to treat their cancers and other chronic diseases such as osteoarthritis and dermatitis.

Our core technology is the first, comprehensive, fully canine phage display libraries, created using the actual RNA extracted from therapeutically removed dog spleens to enable rapid generation of novel, efficacious and tolerable antibody-based therapies, easily administered without the potential of immunogenicity.

About the Speaker

Adriann Sax joined Vetigenics in May 2020 as CEO and Cofounder bringing nearly thirty years of leadership experience from Pharma and Biotech in operations, commercialization and business development with a focus in oncology.

Adriann started her career at Sterling Drug progressing through a series of operating and executive roles with established companies such as Merck, Bristol Myers Squibb and Roche, and led the global launches of leading oncology and immunology drugs. Adriann holds an MBA from the Keller Graduate School and BS in Animal Science from the University of Delaware. She is an active advisor and board member for many industry associations, academic institutions, and non-public company boards.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Steven Theriault

CEO & CSO
Cytophage



Late-Stage company seeking \$10 million+

Company Value Proposition

Cytophage has developed proprietary technologies that can generate bacteriophage in a lab which accelerates the development of phages. Our products are combinations of natural and modified phages that target and destroy specific bacterial organisms. Our phages are 100% harmless to humans, animals, and the environment and up to 100% effective in combating any bacteria. Best of all, they complement and reduce the need for antibiotics, a competitive advantage for farmers.

About the Speaker

Dr. Steven Theriault is a synthetic biologist with 20 years research, public health and entrepreneurial experience. At the Canadian National Microbiology Lab, he worked at the global level on issues related to protecting populations from some of the worst infectious disease outbreaks. In 2017, he founded Cytophage Technologies to unlock the potential of nature's elegant and harmless antibacterial solution – phages. Cytophage has been recognised internationally as an innovative and disruptive technology company.

Cytophage is a human and animal health company that is developing natural, modified and synthetic bacteriophage products to prevent and treat bacterial infections that affect human and animal health. Cytophage's animal bacteriophage cocktails are tailored to address common infections in poultry and swine. Our bacteriophages are inexpensive, quick to produce, harmless to humans and animals, better for the environment and highly effective against exposed bacteria. Our solution presents a new tool to meet new regulatory requirements to reduce the use of antibiotics in livestock farming and stop the global increase in antimicrobial resistance.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Yiannis N. Kaznessis, PhD

CEO

General Probiotics



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Necrotic enteritis (NE) sickens and kills chickens, costing farmers \$6 billion annually. Our anti-clostridia technology lowers NE mortality by 67%.

Our technology also lowers the feed conversion ratio by 6.8 points. In a global market of 70 billion broiler chickens produced annually, this FCR can result in surplus protein production equal to 4.76 billion additional birds.

Ours is a platform technology with estimated gross margins of 65%.

The anti-clostridia asset is the most mature asset and is currently being reviewed by the FDA. We have developed prototypes with activity against Salmonella and Campylobacter in chickens, and against E. coli in swine. We are launching anti-viral assets targeting avian flu and African swine fever.

About the Speaker

Dr. Kaznessis founded General Probiotics and joined the company as Chief Executive Officer in 2018. GP's mission is to fight global food insecurity by supporting and strengthening the production of sustainable, healthy and affordable animal protein.

Kaznessis has 25 years of experience in antimicrobials, synthetic biology, bioinformatics, computational biology, machine learning and microbiome analysis. He has authored 110 refereed papers and the textbook "Statistical Thermodynamics and Stochastic Kinetics."

Kaznessis is the recipient of several honors including the Fulbright Award, the NSF CAREER Award, the 3M Faculty Award, the IBM Young Faculty Award, the Charles E. Bowers Teaching Award and the AIChE CAST Outstanding Young Researcher Award.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Louis Hui

Co-Founder & Managing Partner

Healthy Cow



Pre-Series B company seeking up to £2 million

Company Value Proposition

Healthy Cow is an Ag-Biotech for the dairy sector applying leading-edge bovine microbiomic & metabolomic research to develop preventative products for major cow diseases that have huge animal welfare impacts & economic costs for farmers. Our mission at Healthy Cow is to develop the next-generation alternative products to maintain healthy cows to help farmers save money, rely less on antibiotics & hormones, and produce high-quality milk for their families and community.

Metritis - rooted in the dysbiosis of the microbiome - is a big issue that dairy farmers face as it negatively impacts cows' well-being, milk production, reproduction, & farm profitability. A metritis case can cost an average of \$512/cow, & with an incidence rate of 20-60%, it has an economic burden of \$8 billion/year on the sector.

The emergence of antibiotic-resistant bacteria - partially from overuse in livestock - shows that agriculture needs alternatives.

Our innovation is ProPreg™ - the 1st intravaginal probiotic product that maintains a healthy reproductive microbiome of cattle before & after calving. It supports dairy farmers' efforts to proactively care for their cows, produce high-quality milk, and reduce their use of antibiotics.

About the Speaker

Louis is a driven entrepreneur and former venture capitalist who strives to make a positive impact on society by supporting innovative biotechnologies that can significantly improve health and society. Louis recognizes the major macro-trends and threats of global food insecurity, including the current issues facing the dairy industry. With his strong understanding of dairy, he envisions Healthy Cow to develop new tools that will enable farmers to "dairy better".



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Jack Heinemann

President & Chief Operating Officer

Isomark

Pre-Series B company seeking up to \$2 million



Company Value Proposition

Isomark's core value proposition is to improve animal health through early infection detection and to become the gold standard for early infection detection. There is a dramatic cost-benefit correlation between early detection of infections and their treatment. The earlier an infection is confirmed, the more effective and less expensive the course of treatment and care.

Isomark monitors exhaled breath to detect infections caused by viral, bacterial, and fungal sources soon after onset, along with response to antimicrobial treatment. Non-invasive/rapid detection technology is focused on changes in natural carbon isotopes in exhaled breath CO₂ and other metabolites, called "breath print". Breath print can be thought of as the "temperature of the immune system," providing pre-symptomatic biomarkers for infections at the earliest time, providing up to two days' notice before conventional methods. Early detection provides the ability to begin treating infections at their earliest point resulting in improved treatment success, reduced antibiotic use/costs, and lower morbidity/mortality losses due to disease.

About the Speaker

For 25 years, Jack Heinemann has provided entrepreneurial leadership in two Fortune 500 companies and three smaller companies.

As Director of International Business Development for the Wisconsin Department of Agriculture, he developed policies and programs which supported Wisconsin Agri Business growth. Jack developed the Wisconsin International Dairy Export (WIDE) program to support the growth of Wisconsin dairy exports in the Middle East and in South America. With the State of Wisconsin Department of Agriculture, he developed a global network of agri-business and government relationships that have proven helpful to securing initial funding for Isomark.

He holds a Mechanical Engineering Degree from the University of Wisconsin - Madison, and a Master's in Business Administration from the University of Wisconsin - Oshkosh.

He currently resides near Madison, Wisconsin.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Jenny Filbey

CEO

Mazen Animal Health



Series B+ company seeking \$2-10 million

Company Value Proposition

Mazen is revolutionizing animal disease prevention with orally-delivered plant-based veterinary vaccines offering customers cost-effective, safe to deliver, efficacious, room temperature stable vaccines to increase productivity & ensure food supply.

The expanding world population is creating pressure on protein suppliers to increase production density leading to greater prevalence of animal diseases. Vaccination provides disease prevention, but injectable vaccines are costly to administer, increase the biosecurity risk of disease spread & disrupt the animals. Mazen offers effective disease prevention by dosing the vaccine with feed, helping animal producers increase their production systems ROI. Additionally, more efficient production positively impacts the environment.

About the Speaker

As a tenacious and driven leader, Jenny Filbey has dedicated her career to the translation of science into meaningful commercial businesses. Jenny's specific experience in assembling science, creating and funding start-ups, coupled with her breadth of experience across the life science industry has proven to benefit Mazen. Determined to disrupt the animal vaccine market, Jenny has established a world class team, leading them in the development and commercialization of Mazen's oral vaccines.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Randall Tosh

Founder & CEO

Phoreus



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Phoreus Biotech produces nanocarriers driving the next generation of genetic medicine and offers substantial increases in the efficacy of existing veterinary drugs and therapeutics. We are a bioscience disruptor with two patented nanocarrier platforms: Branched Amphipathic Peptide Capsules (BAPC™) and Corraling Amphipathic Peptide Colloids (CAPC™). These nanocarriers can revolutionize vaccine development, cancer therapeutics, small molecule delivery, and gene editing/therapy.

About the Speaker

Randall Tosh is the Chief Executive Officer and a Founder of Phoreus Biotechnology, Inc. He is responsible for the development and commercialization of the Branched Amphipathic Peptide Capsules (BAPC) and Corraling Amphipathic Peptide Colloids (CAPC) technology platforms licensed from the Kansas State University Research Foundation.

Previously, he was the executive vice president and a director of SmartVet Holdings, Inc. where he was responsible for development and management of US and Latin American markets for SmartVet's proprietary animal health technology platforms. He had a leadership role in research and development and regulatory compliance activities related to a range of animal health products designed for delivery with the company's VetGun™ System.

He holds a B.S. degree in Agriculture from Kansas State University.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS

PorkLogic

Harrison Moss

Co-Founder & CEO

Porklogic



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Currently, within the U.S. swine industry, 20-30% of weaned piglets fail to reach the market at full value due to health and wellness issues encountered during the production cycle. The inability to detect sick individuals before they exhibit overt signs of distress is a major limitation preventing pork producers from reducing significant associated economic losses. Porklogic.ai is a technology/product representing a radical innovation that directly overcomes this limitation. This IoT-based system allows producers to

1. Measure physiological markers of stress and sickness behaviors in animals,
2. Monitor animal health in real-time remotely
3. Extend traceability and tracking from farm to fork

Furthermore, this innovative IoT-based big data system allows digital touchpoints that seamlessly connect producers, packers, food companies, veterinarians, packers, pharma, retailers/restaurants, and consumers to ultimately create novel branding opportunities and to greatly increase consumer confidence in the safety and wholesomeness of pork products.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Yael Alter

Co-Founder & CEO
SOOS Technology



Pre-Series B company seeking up to \$2 million

Company Value Proposition

Soos Technology is an Israeli agtech startup developing a solution to the egg-production industry's greatest challenge – male chick extermination. Every year 7.5 billion male chicks are exterminated because they can't lay eggs or produce meat for the industry. This is a serious animal welfare, economic, ecological, and regulatory issue. Our solution transforms male layers into functional females that can lay eggs. Our technology uses sound waves to affect the gonadal development of the embryos.

Our solution provides the industry with more egg-laying females using the same resources. This provides our clients with more product while saving chicks lives. This also saves lots of ecological waste such as electricity, water, feed, and human resources during the breeding and incubation stages.

With countries such as Germany and France soon banning the male-chick culling practice, now is the time for the industry to adopt a solution that will decrease/eliminate the extermination practice.

The added value of each additional female is roughly \$2 (\$1.5 in added revenue for selling the chick + \$0.5 saved on extermination costs). With 7.5B males killed annually, we can provide the industry with \$15B in added value.

About the Speaker

Yael Alter, CEO & Co-founder, brings 20+ years of entrepreneurial experience as the CEO of global agricultural & poultry projects companies such as Agropaz and Yamko, which have provided Yael with poultry and agriculture industry knowledge and connections.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Matthew Rooda

Co-Founder & CEO

SwineTech



Pre-Series B company seeking up to \$2 million

Company Value Proposition

SwineTech provides solutions that bring welfare assurance and supply chain transparency to the swine industry. Our product, PigFlow, tracks all pig movements as well as the inputs and actions performed by an individual in real-time. Producers now have the ability to ensure process compliance and empower all employees to minimize mistakes, and offer a high quality of care to every pig. This translates into happier employees, more effective teams, fewer pig deaths, and reduced costs of production.

The swine industry has reported a turnover rate of 35.03% respectively, and in many cases, it will exceed 100%. This represents \$4.05 billion in annual losses and an annual loss of on-site knowledge, experience, and skill sets. Additionally, 430 million piglets die each year, and there are currently no producers in the US that receive any process compliance data. All evaluations and decision making are based on in-person observations.

Our product, PigFlow, allows producers to set SOP guidelines and can evaluate each team's compliance to those expectations. This brings real-time animal health and process insights to the fingertips of managers that can then make corrective actions to help keep people well trained and pigs healthy.

About the Speaker

Matthew Rooda is the Co-Founder and CEO SwineTech, Inc. to solve the global issue of labor inefficiencies and pig mortalities within the pork industry.

Rooda led the SwineTech team through the Pearse Lyons Accelerator in Dublin, Ireland, raised more than \$6 million in venture capital, has grown the team to 20+ employees, and managed business development efforts in North America, Europe, and Asia. He has won awards from Microsoft, MIT, Princeton, the National Inventors Hall of Fame, was named the American Farm Bureau Entrepreneur of the Year, and was selected as part of the 2018 Forbes 30 under 30 class in the category Manufacturing and Industry.



INNOVATION SHOWCASE FINALISTS PRODUCTION ANIMALS



Kerryann Kocher

CEO
Vytelle



Late-Stage company seeking £10 million+

Company Value Proposition

Vytelle is a precision livestock company reshaping how cattle producers worldwide optimize their herds. Through Vytelle's integrated technology platform, generations of genetic gains can be made in just a few years. This allows producers to sustainably deliver more protein with fewer inputs, helping to ensure meat and milk are viable, competitive food choices for future generations.

There are two high-stake producer decisions that drive genetic progress in the global cattle industry; mating selection (who should I breed) and reproduction method (how should I breed). When utilizing traditional reproduction methods and a poor mating selection, discovery can take up to 2-5 years with lasting effects for producers. With the increase in demand for global protein, emerging alternative protein choices and consumers' demand for sustainable meat and milk, the global cattle industry does not have time for poor decisions.

In addition, the demand for high-quality and nutritious protein continues to increase, and cattle are the least efficient protein producer. This, coupled with changing consumer demands for more sustainably produced meat and milk, and the arrival of alternative protein sources, such as cell or plant-based products, put cattle producers in a fight for survival.

About the Speaker

Kerryann Kocher was appointed as Vytelle's Chief Executive Officer in 2020. Prior to her current appointment, Kerryann founded and led Rock Road Consulting, a boutique business consulting practice dedicated to animal agriculture and focused on helping clients translate their technology into meaningful value for farmers, ranchers and producers. At Rock Road, Kerryann served a range of clients from multi-national animal health companies to venture capital firms and start-ups.





OUR PLATFORM: THE VIRTUAL EXPERIENCE

TOP 10 BENEFITS OF DIGITAL

- 1 Tailor Your Agenda
- 2 More Audience Participation
- 3 Improved Audience Visibility
- 4 On-Demand Content
- 5 High-quality Speakers
- 6 More Networking Opportunities
- 7 Save Time & Money
- 8 Increased Content
- 9 More insights
- 10 Business Development Opportunities

TALK TO OUR TEAM TO FIND OUT MORE

PREVIEW OUR PLATFORM

A virtual event may be a first for many, take a look at our content and networking platforms to see how easy it really is!



VENUE & PRICING

PASS TYPE	EARLY BIRD (until 21 April 2021)	STANDARD RATE
TIER ONE Start-ups, VCs, Angel Investors Please note: Those offering consultancy or market intelligence services do not qualify for this rate	\$649	\$749
TIER TWO Animal Health Companies, Pharmaceutical Companies, CROs, CMOs, Consultants, M&A Advisors, Private Equity, Incubators, Accelerators and Distributors	\$1,699	\$1,999

BIG SAVINGS WITH BIG BOOKINGS

SAVE 10% - Book a team of 3+

SAVE 15% - Book a team of 5+

REGISTER
HERE

Team discounts are only valid on industry rates and not in conjunction with any other offer or promotion. Payment Terms: Please note that all prices are plus VAT and a \$79 processing fee will apply to any invoices requested. All Prices are in GBP. All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above. No discount offers can be combined with any other offer. Please note if you are a UK based company VAT will be added to your total payment. Please view our Cancellation Policy. QUESTIONS? Please email events@kisacoresearch.com.

